• 

  STOCK ANALYST UPDATE

  Solid Drug Sales, Cost Control Boost Johnson & Johnson

  The first-quarter performance reinforces our wide moat rating.

  • What to Expect From Big Pharma's Earnings
• 

  STOCK STRATEGIST

  We Like Goldman's Transformation

  We think it should be positive for those with a long-term investment horizon.

  • Financial Services: Interest-Rate Expectations Have Pressured Performance
• 

  US VIDEOS

  What Bank Earnings Say About the Health of the Economy

  Commentary from the four largest U.S. banks has been positive, and fundamentals still look OK.

Article Library

• Stock Strategist Archive
• Industry Report Archive
• Ultimate Stock-Pickers

StockInvesting

• A Mixed Quarter for Citigroup
• What to Expect From Big Pharma's Earnings
• Pinning a Narrow Moat on the Pinterest Board
• Market Doesn't Appreciate Dominion's Strategy Pivot
• Bed Bath Continues to Cede Share, Stock Overpriced

• Changes at Millicom Pique Our Interest
• Lowering Our Pharma Distributor Moat Ratings and Valuations
• No Excess Baggage at Pacifico
• First-Quarter Trends in 14 Charts
• 3 REITS Providing Above-Average Dividends
• We See Steady Growth for Bayer
• Firewall Leader Set to Expand
• A Lower Moat Rating for Kingfisher
• 30 Undervalued Stocks
• Technology: Semiconductors the Most Attractive Tech Subsector
• A Cheap, Wide-Moat Health Insurer
• Virtual Banking Launch Shouldn't Erode Hong Kong Banks' Advantages